KR20170008239A - 세리티닙 제제 - Google Patents

세리티닙 제제 Download PDF

Info

Publication number
KR20170008239A
KR20170008239A KR1020167032886A KR20167032886A KR20170008239A KR 20170008239 A KR20170008239 A KR 20170008239A KR 1020167032886 A KR1020167032886 A KR 1020167032886A KR 20167032886 A KR20167032886 A KR 20167032886A KR 20170008239 A KR20170008239 A KR 20170008239A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
seritinib
tablet
binder
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167032886A
Other languages
English (en)
Korean (ko)
Inventor
세바스티엔 브렐스
시몬 엔슬린
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53298568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20170008239(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20170008239A publication Critical patent/KR20170008239A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
KR1020167032886A 2014-05-29 2015-05-27 세리티닙 제제 Ceased KR20170008239A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462004359P 2014-05-29 2014-05-29
US62/004,359 2014-05-29
PCT/IB2015/053966 WO2015181739A1 (en) 2014-05-29 2015-05-27 Ceritinib formulation

Publications (1)

Publication Number Publication Date
KR20170008239A true KR20170008239A (ko) 2017-01-23

Family

ID=53298568

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167032886A Ceased KR20170008239A (ko) 2014-05-29 2015-05-27 세리티닙 제제

Country Status (27)

Country Link
US (4) US20170112834A1 (enExample)
EP (1) EP3148513B1 (enExample)
JP (3) JP6679578B2 (enExample)
KR (1) KR20170008239A (enExample)
CN (1) CN106456640B (enExample)
AR (1) AR100625A1 (enExample)
AU (3) AU2015265470A1 (enExample)
BR (1) BR112016027580A8 (enExample)
CA (1) CA2948291A1 (enExample)
CL (1) CL2016003047A1 (enExample)
DK (1) DK3148513T3 (enExample)
EA (1) EA036922B1 (enExample)
EC (1) ECSP16096826A (enExample)
ES (1) ES2792574T3 (enExample)
HU (1) HUE048950T2 (enExample)
IL (1) IL248835B (enExample)
MX (1) MX373624B (enExample)
PE (1) PE20170313A1 (enExample)
PH (1) PH12016502272A1 (enExample)
PL (1) PL3148513T3 (enExample)
PT (1) PT3148513T (enExample)
SG (1) SG11201609208UA (enExample)
SI (1) SI3148513T1 (enExample)
TN (1) TN2016000484A1 (enExample)
TW (1) TWI721946B (enExample)
UY (1) UY36140A (enExample)
WO (1) WO2015181739A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI721946B (zh) 2014-05-29 2021-03-21 瑞士商諾華公司 色瑞替尼調配物
CN106176752B (zh) * 2015-05-07 2020-06-23 石药集团中奇制药技术（石家庄）有限公司 色瑞替尼药物组合物
CN109381440A (zh) * 2018-11-15 2019-02-26 威海贯标信息科技有限公司 一种艾乐替尼组合物
CN113244236B (zh) * 2021-06-01 2023-02-03 上海市第一人民医院 色瑞替尼在制备治疗甲状腺相关眼病的药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3632778A (en) * 1970-06-10 1972-01-04 Hoffmann La Roche Tablets containing l-dopa
TW200803850A (en) * 2006-03-06 2008-01-16 Wyeth Corp Tablet formulations and processes
US20090239920A1 (en) 2006-11-21 2009-09-24 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080175901A1 (en) 2006-11-21 2008-07-24 Wyeth Pharmaceutical formulations of a crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
JP5208123B2 (ja) * 2006-12-08 2013-06-12 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
EA019941B1 (ru) * 2006-12-08 2014-07-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
EP2090297A1 (en) 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
ES2377869T3 (es) 2008-09-04 2012-04-02 Cargill, Incorporated Fabricación de comprimidos de eritritol
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
CN102480998B (zh) 2009-08-18 2016-05-25 卡吉尔公司 赤藓醇和异麦芽酮糖醇的压片
JP5596799B2 (ja) 2010-05-11 2014-09-24 田辺三菱製薬株式会社 カナグリフロジン含有錠剤
CN103200828A (zh) 2010-09-07 2013-07-10 卡吉尔公司 固体化糖醇混合物
TWI721946B (zh) 2014-05-29 2021-03-21 瑞士商諾華公司 色瑞替尼調配物

Also Published As

Publication number Publication date
PH12016502272A1 (en) 2017-02-06
AU2019232937B2 (en) 2020-10-15
US20200009141A1 (en) 2020-01-09
CN106456640B (zh) 2021-05-14
US20210154194A1 (en) 2021-05-27
MX2016015736A (es) 2017-03-16
MX373624B (es) 2020-05-22
BR112016027580A2 (pt) 2017-08-15
JP6679578B2 (ja) 2020-04-15
EA036922B1 (ru) 2021-01-15
IL248835A0 (en) 2017-01-31
EP3148513A1 (en) 2017-04-05
PL3148513T3 (pl) 2020-08-24
AU2019232937A1 (en) 2019-10-10
US11000523B2 (en) 2021-05-11
EA201692310A1 (ru) 2017-04-28
SI3148513T1 (sl) 2020-07-31
WO2015181739A1 (en) 2015-12-03
PT3148513T (pt) 2020-05-27
PE20170313A1 (es) 2017-04-18
JP2020114834A (ja) 2020-07-30
AU2018203007A1 (en) 2018-05-17
JP7084955B2 (ja) 2022-06-15
TN2016000484A1 (en) 2018-04-04
US12357630B2 (en) 2025-07-15
UY36140A (es) 2016-01-08
HUE048950T2 (hu) 2020-09-28
EP3148513B1 (en) 2020-02-26
IL248835B (en) 2020-05-31
DK3148513T3 (da) 2020-05-25
CA2948291A1 (en) 2015-12-03
SG11201609208UA (en) 2016-12-29
ECSP16096826A (es) 2018-04-30
CL2016003047A1 (es) 2017-04-07
TWI721946B (zh) 2021-03-21
BR112016027580A8 (pt) 2021-06-29
US20190022095A1 (en) 2019-01-24
TW201613580A (en) 2016-04-16
CN106456640A (zh) 2017-02-22
AU2018203007B2 (en) 2019-07-18
JP2017520619A (ja) 2017-07-27
JP2022078236A (ja) 2022-05-24
AR100625A1 (es) 2016-10-19
US20170112834A1 (en) 2017-04-27
AU2015265470A1 (en) 2016-11-24
ES2792574T3 (es) 2020-11-11

Similar Documents

Publication Publication Date Title
CN106943355B (zh) 药物组合物
US12357630B2 (en) Ceritinib formulation
EP1781260A1 (en) Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
TW201818936A (zh) 一種吡啶酮類衍生物醫藥組成物及其製備方法
WO2013189305A1 (zh) 缬沙坦氨氯地平复方固体制剂及其制备方法
CN108174596A (zh) 包含8-[(3r)-3-氨基-1-哌啶基]-7-(2-丁炔-1-基)-3,7-二氢-3-甲基-1-[4-甲基-2-喹唑啉基)甲基]-1h-嘌呤-2,6-二酮或其药学上可接受的盐的药物组合物
JP2023071921A (ja) 様々な用量のレナリドミドの経口用錠剤組成物
CN103768068A (zh) 一种波生坦药物组合物
CN112512511B (zh) 具有cdc7抑制剂的药物组合物
WO2006123213A1 (en) Modified release formulations of gliclazide
WO2022042646A1 (zh) 盐酸鲁拉西酮组合物及其制备方法
CA2927437C (en) Pharmaceutical dosage forms containing sodium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1h-1,2,3-triazol-1-yl)-1h-pyrazol-5-olate
EP2968167A1 (en) Dosage form comprising crizotinib
JP5563371B2 (ja) クエチアピンフマル酸塩含有経口用錠剤
HK1229715B (en) Ceritinib formulation
HK1229715A1 (en) Ceritinib formulation
CN110227067B (zh) 一种盐酸普拉克索缓释片及其制备方法
TW202339723A (zh) 一種固體藥物組合物
HK40119354A (en) Pharmaceutical preparation

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20161124

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200513

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210915

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20211223

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210915

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I